[ { "evidence_id": "EV-0101", "claim": "SURMOUNT-1 reported mean weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks versus 2.4% with placebo", "source_title": "Tirzepatide Once Weekly for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0101.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0102", "claim": "SURMOUNT-5 reported \u221220.2% weight change with tirzepatide versus \u221213.7% with semaglutide at 72 weeks", "source_title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2416394", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0102.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0103", "claim": "SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, weight, hypoxic burden, hsCRP and systolic blood pressure", "source_title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity", "source_url": "https://www.nejm.org/doi/10.1056/NEJMoa2404881", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0103.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0104", "claim": "Three years of tirzepatide in obesity with prediabetes markedly lowered progression to type 2 diabetes versus placebo", "source_title": "Tirzepatide for Obesity Treatment and Diabetes Prevention", "source_url": "https://www.nejm.org/doi/abs/10.1056/NEJMoa2410819", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0104.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0105", "claim": "SURMOUNT-4 examined continued tirzepatide versus withdrawal for maintenance of weight reduction", "source_title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial", "source_url": "https://jamanetwork.com/journals/jama/fullarticle/2812936", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0105.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Registry identifier, sample size and numeric results not yet captured from the full text. Do not publish result figures until they are." }, { "evidence_id": "EV-0201", "claim": "FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need", "source_title": "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List", "source_url": "https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list", "source_type": "Federal agency press announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0201.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0202", "claim": "The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552", "source_title": "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B", "source_url": "https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0202.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0203", "claim": "FDA extended the comment period; comments must be submitted by 30 July 2026", "source_title": "Comment period extension, List of Bulk Drug Substances Under Section 503B", "source_url": "https://www.federalregister.gov/documents/full_text/html/2026/06/26/2026-12937.html", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0203.png", "strength": "Primary", "status": "verified", "next_review": "2026-07-31", "notes": "Live deadline. Re-check on 31 July 2026 and again when a final determination publishes." }, { "evidence_id": "EV-0301", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $215/month on the month-to-month plan, $215 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0301.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0302", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $195/month on the 3-month prepaid plan, $585 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0302.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0303", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $190/month on the 6-month prepaid plan, $1140 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0303.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0304", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $186/month on the 12-month prepaid plan, $2232 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0304.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0305", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $165/month on the month-to-month plan, $165 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0306", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $149/month on the 3-month prepaid plan, $447 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0307", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $147/month on the 6-month prepaid plan, $882 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0308", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $145/month on the 12-month prepaid plan, $1740 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0308.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0309", "claim": "NexLife publishes tirzepatide (microdose) at $189/month on the month-to-month plan, $189 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0310", "claim": "NexLife publishes tirzepatide (microdose) at $159/month on the 3-month prepaid plan, $479 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0311", "claim": "NexLife publishes tirzepatide (microdose) at $150/month on the 6-month prepaid plan, $899 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0312", "claim": "NexLife publishes tirzepatide (microdose) at $147/month on the 12-month prepaid plan, $1764 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0313", "claim": "NexLife publishes semaglutide (microdose) at $129/month on the month-to-month plan, $129 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0314", "claim": "NexLife publishes semaglutide (microdose) at $117/month on the 3-month prepaid plan, $357 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0315", "claim": "NexLife publishes semaglutide (microdose) at $114/month on the 6-month prepaid plan, $684 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0316", "claim": "NexLife publishes semaglutide (microdose) at $110/month on the 12-month prepaid plan, $1320 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0317", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $229/month on the month-to-month plan, $229 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0318", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $219/month on the 3-month prepaid plan, $657 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0319", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $205/month on the 6-month prepaid plan, $1230 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0320", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $199/month on the 12-month prepaid plan, $2388 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0321", "claim": "NexLife publishes semaglutide (sublingual ODT) at $199/month on the month-to-month plan, $199 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0322", "claim": "NexLife publishes semaglutide (sublingual ODT) at $185/month on the 3-month prepaid plan, $597 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0323", "claim": "NexLife publishes semaglutide (sublingual ODT) at $177/month on the 6-month prepaid plan, $1062 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0324", "claim": "NexLife publishes semaglutide (sublingual ODT) at $165/month on the 12-month prepaid plan, $1980 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0350", "claim": "NexLife states it is LegitScript-certified", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify directly in the LegitScript certification lookup, not on the provider's own page." }, { "evidence_id": "EV-0351", "claim": "NexLife states it works exclusively with LegitScript-certified, NABP-accredited pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Name the specific pharmacy or pharmacies and verify each accreditation with the accrediting body." }, { "evidence_id": "EV-0352", "claim": "NexLife states every batch undergoes independent third-party testing for potency, sterility, pH and endotoxin", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Ask who performs the testing, whether a certificate of analysis is available to patients, and for a sample COA." }, { "evidence_id": "EV-0353", "claim": "NexLife states compounded medication is prepared by U.S.-licensed 503A compounding pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "One NexLife page references 503A; third-party coverage references both 503A and 503B. Resolve which applies, because the regulatory position and the pending FDA 503B bulks proposal differ materially between them." }, { "evidence_id": "EV-0354", "claim": "NexLife states availability in all 50 states", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify state by state against checkout or written support confirmation. A national marketing claim is not evidence of availability in any specific state." }, { "evidence_id": "EV-0355", "claim": "NexLife cites SURMOUNT-1 as showing average weight loss of up to 24.3% over 72 weeks", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "The SURMOUNT-1 efficacy-estimand results published in NEJM were 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg. Establish which analysis the 24.3% figure comes from before repeating it. Separately, SURMOUNT-1 studied the FDA-approved product, not a compounded preparation, so the result does not transfer automatically." }, { "evidence_id": "EV-0356", "claim": "NexLife references self-reported outcomes from 518 members", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Self-reported member data is not trial evidence. If cited at all, label it as self-reported, state the denominator and response rate, and never present it beside trial figures without that distinction." }, { "evidence_id": "EV-0106", "claim": "SUMMIT reported a 38% reduction in the combined endpoint of death and worsening heart-failure events in obesity-related HFpEF", "source_title": "Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy", "source_url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.11.001", "source_type": "Peer-reviewed substudy of a randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0106.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Capture the primary SUMMIT publication DOI and the absolute event rates before publishing the relative risk reduction alone." }, { "evidence_id": "EV-0107", "claim": "Retatrutide phase 3 figures circulating in commercial secondary sources are unconfirmed against a primary publication", "source_title": "Retatrutide phase 2 trial", "source_url": "https://doi.org/10.1056/NEJMoa2301972", "source_type": "Peer-reviewed randomised controlled trial (phase 2)", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary for phase 2 only", "status": "reported", "next_review": "2026-08-24", "notes": "Several sites publishing phase 3 retatrutide figures are peptide vendors or carry provider advertising inside clinical copy. Treat as unverified." }, { "evidence_id": "EV-04001", "claim": "Found lists tirzepatide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04002", "claim": "NexLife lists tirzepatide (compounded injectable) at $186 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($2,232). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04003", "claim": "Oak Longevity lists tirzepatide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "third_party", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-04004", "claim": "Shed lists tirzepatide (compounded injectable) at $245 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04005", "claim": "Mochi Health lists tirzepatide (compounded injectable) at $278 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04006", "claim": "Enhance.MD lists tirzepatide (compounded injectable) at $280 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04007", "claim": "Eden lists tirzepatide (compounded injectable) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04008", "claim": "Noom Med lists tirzepatide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04009", "claim": "TrimRx lists tirzepatide (compounded injectable) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04010", "claim": "MEDVi lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04011", "claim": "bmiMD lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04012", "claim": "NexLife lists tirzepatide (compounded microdose) at $147 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,764). Month-to-month $189; 6-month $150; 3-month $160. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04013", "claim": "Enhance.MD lists tirzepatide (compounded microdose) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04014", "claim": "Shed lists tirzepatide (compounded microdose) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04015", "claim": "bmiMD lists tirzepatide (compounded microdose) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04016", "claim": "NexLife lists tirzepatide (compounded oral / ODT) at $199 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($2,388). Month-to-month $229; 6-month $205; 3-month $219. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04017", "claim": "Henry Meds lists tirzepatide (compounded oral / ODT) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04018", "claim": "NexLife lists semaglutide (compounded microdose) at $110 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,320). Month-to-month $129; 6-month $114; 3-month $119. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04019", "claim": "Shed lists semaglutide (compounded microdose) at $149 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04020", "claim": "Oak Longevity lists semaglutide (compounded injectable) at $133 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "third_party", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-04021", "claim": "NexLife lists semaglutide (compounded injectable) at $145 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($1,740). Month-to-month $165; 6-month $147; 3-month $149. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04022", "claim": "Found lists semaglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04023", "claim": "Shed lists semaglutide (compounded injectable) at $175 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04024", "claim": "Mochi Health lists semaglutide (compounded injectable) at $178 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04025", "claim": "Eden lists semaglutide (compounded injectable) at $198 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04026", "claim": "Noom Med lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04027", "claim": "TrimRx lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04028", "claim": "Enhance.MD lists semaglutide (compounded injectable) at $212 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04029", "claim": "bmiMD lists semaglutide (compounded injectable) at $289 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04030", "claim": "Henry Meds lists semaglutide (compounded injectable) at $297 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04031", "claim": "MEDVi lists semaglutide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04032", "claim": "NexLife lists semaglutide (compounded oral / ODT) at $165 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($1,980). Month-to-month $199; 6-month $177; 3-month $185. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04033", "claim": "Henry Meds lists semaglutide (compounded sublingual) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04034", "claim": "Shed lists semaglutide (compounded sublingual) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04035", "claim": "Shed lists semaglutide (compounded sublingual) at $229 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04036", "claim": "Henry Meds lists semaglutide (compounded oral / ODT) at $249 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04037", "claim": "MEDVi lists semaglutide (compounded oral / ODT) at $369 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04038", "claim": "Found lists liraglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04039", "claim": "Henry Meds lists liraglutide (compounded injectable) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04040", "claim": "LillyDirect lists orforglipron (Foundayo) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "0.8 mg starter, Self Pay Journey Program. Rises to $199 (2.5 mg), $299 (5.5/9 mg), $349 (14.5/17.2 mg); drops to $299 on refill within 45 days.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04041", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Wegovy tablets, 1.5 mg and 4 mg.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04042", "claim": "LillyDirect lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $299 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "2.5 mg starter vial, Self Pay Journey Program. 5 mg $399; 7.5\u201315 mg $449, requiring refill within 45 days to hold the rate.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04043", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $349 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Month three onward, all maintenance doses. Reduced from $499 in November 2025.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04044", "claim": "PlushCare lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $319 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04045", "claim": "WeightWatchers Clinic lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $323 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04046", "claim": "Hims lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04047", "claim": "Ro lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $348 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04048", "claim": "Found lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $447 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04049", "claim": "Eden lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $1794 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04050", "claim": "Hers lists tirzepatide (Mounjaro) (brand injectable, FDA-approved) at $2048 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-0108", "claim": "SURMOUNT-3 reported \u221218.4% additional weight reduction after a lifestyle lead-in versus +2.5% placebo", "source_title": "Wadden TA et al., Nature Medicine 2023", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0109", "claim": "SURMOUNT-4 reported 5.5% further loss on continued treatment against 14.0% regain after withdrawal", "source_title": "Aronne LJ et al., JAMA 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0110", "claim": "SURPASS-2 reported HbA1c reductions of 2.01\u20132.30% with tirzepatide versus 1.86% with semaglutide 1 mg", "source_title": "Fr\u00edas JP et al., N Engl J Med 2021", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0111", "claim": "SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events", "source_title": "SURPASS-CVOT, 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0112", "claim": "SURMOUNT-1 publishes two estimands; the treatment-regimen figures are 15.0/19.5/20.9% and the efficacy figures are 16.0/21.4/22.5%", "source_title": "Jastreboff AM et al., N Engl J Med 2022", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0501", "claim": "The Federation of State Medical Boards maintains a public directory of every state medical board", "source_title": "FSMB \u2014 Contact a State Medical Board", "source_url": "https://www.fsmb.org/contact-a-state-medical-board/", "source_type": "National regulatory federation directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "FSMB represents 70 state medical and osteopathic boards across the US, its territories and DC." }, { "evidence_id": "EV-0502", "claim": "The National Association of Boards of Pharmacy maintains a public directory of state boards of pharmacy", "source_title": "NABP \u2014 Contact Your Board", "source_url": "https://nabp.pharmacy/about/boards-of-pharmacy/", "source_type": "National regulatory association directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Active member boards cover all 50 states, DC, Guam, Puerto Rico and the Virgin Islands." }, { "evidence_id": "EV-0113", "claim": "Orforglipron (Foundayo) was FDA-approved on 1 April 2026 for chronic weight management, with reported mean weight reduction of approximately 11% to 12.4% at the highest dose over 72 weeks", "source_title": "FDA approves Lilly's Foundayo (orforglipron)", "source_url": "https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Manufacturer announcement. The efficacy figure varies between 11% and 12.4% across sources without a consistently stated estimand. Capture the ATTAIN-1 publication before charting a single number." }, { "evidence_id": "EV-0114", "claim": "OASIS 4 reported 13.6% mean weight reduction on the treatment-policy estimand and 16.6% among adherent participants, against 2.2% and 2.7% with placebo", "source_title": "Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025;393(11):1077-1087", "source_url": "https://doi.org/10.1056/NEJMoa2500969", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0115", "claim": "The Wegovy pill (oral semaglutide 25 mg) was FDA-approved on 22 December 2025 for weight management and for reducing the risk of major adverse cardiovascular events", "source_title": "Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management", "source_url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0116", "claim": "LillyDirect self-pay pricing for Foundayo runs $149 to $349 by dose, with $299 on the top two doses when timely refill requirements are met; $25 per month with an eligible commercial savings card and $50 for eligible Medicare Part D patients from 1 July 2026", "source_title": "FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity", "source_url": "https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Trade press reporting of manufacturer pricing. Re-capture from LillyDirect's own page before describing as verified." }, { "evidence_id": "EV-0601", "claim": "FDA states that registration as an outsourcing facility means only that the agency has received the required information. It does not mean the facility is making FDA-approved drugs, and it does not mean the facility is in compliance with CGMP requirements or the other conditions of section 503B", "source_title": "Questions and Answers: Outsourcing Facility Registration", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the agency's own wording and it is stronger than the common summary. CGMP compliance is a legal requirement under 503B; registration is not evidence that a given facility meets it." }, { "evidence_id": "EV-0602", "claim": "FDA maintains a public register of outsourcing facilities and a searchable Outsourcing Facility Product Report database covering the last four reporting periods", "source_title": "Information for Outsourcing Facilities", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency register", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "A facility is removed from the list when it is no longer registered. Check currency, not merely presence." }, { "evidence_id": "EV-0603", "claim": "Section 503B was created by the Drug Quality and Security Act, signed into law on 27 November 2013", "source_title": "Information for Outsourcing Facilities \u2014 Drug Quality and Security Act", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0604", "claim": "FDA's registration guidance for outsourcing facilities is issued under docket FDA-2013-N-1429", "source_title": "Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0605", "claim": "FDA's 2019 guidance interpreting clinical need for the 503B bulks list states that clinical need is distinct from supply constraints or cost considerations", "source_title": "FDA Proposes to Exclude GLP-1 Receptor Agonists from the 503B Bulks List \u2014 analysis", "source_url": "https://www.frierlevitt.com/articles/fda-glp1-503b-bulks-list-proposed-exclusion-semaglutide-tirzepatide-liraglutide/", "source_type": "Legal analysis of federal guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve FDA's 2019 clinical-need guidance directly and cite the agency document rather than this analysis before relying on the wording." }, { "evidence_id": "EV-0606", "claim": "PCAB accreditation is administered through ACHC", "source_title": "503A vs 503B compounding pharmacy \u2014 industry reference", "source_url": "https://tccompound.com/blogs/health-hub/503a-vs-503b", "source_type": "Industry source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Confirm directly with ACHC and capture the public accreditation lookup before describing any provider's PCAB claim as verified." }, { "evidence_id": "EV-0607", "claim": "Reporting indicates FDA issued warning letters to approximately 30 telehealth firms over claims that compounded GLP-1s are identical to branded drugs, with 50 or more warning letters to compounders and distributors during 2025", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Counts come from trade press. Verify against FDA's own warning letter database before publishing a number." }, { "evidence_id": "EV-0608", "claim": "Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at levels up to 86%", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press reporting a litigation allegation", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is an allegation in litigation by a competitor manufacturer, not an established finding. Do not publish as fact. If used at all, attribute to the litigation and note it is contested." }, { "evidence_id": "EV-0701", "claim": "The Zepbound label directs starting at 2.5 mg once weekly for 4 weeks, increasing to 5 mg, then increasing in 2.5 mg increments no sooner than every 4 weeks, to a maximum of 15 mg once weekly", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The label sets a minimum interval, not a fixed calendar. Escalation is based on tolerability and response." }, { "evidence_id": "EV-0702", "claim": "The label states the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the label's own wording. It is the strongest available support for the point that an advertised price quoted at 2.5 mg is not the price of treatment." }, { "evidence_id": "EV-0703", "claim": "The recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly. 7.5 mg and 12.5 mg are titration steps, not recommended maintenance dosages", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Correcting an earlier version of our titration table, which presented all six strengths as a sequential schedule." }, { "evidence_id": "EV-0704", "claim": "Zepbound carries a boxed warning for thyroid C-cell tumours observed in rats. Human relevance has not been determined. It is contraindicated in personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Anaphylaxis and angioedema have been reported. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection, per the label." }, { "evidence_id": "EV-0705", "claim": "The label states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Directly relevant to this market: a patient using a compounded preparation alongside a branded product, or alongside another GLP-1, is doing something the label advises against." }, { "evidence_id": "EV-0706", "claim": "Zepbound is indicated both for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The OSA indication followed the SURMOUNT-OSA programme." }, { "evidence_id": "EV-0707", "claim": "Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, administered once weekly at any time of day with or without meals, into the abdomen, thigh or upper arm with site rotation", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0708", "claim": "In SURMOUNT-1, discontinuation due to an adverse event ranged from 4.3% to 7.1% across tirzepatide doses against 2.6% with placebo, and 50% and 57% of the 10 mg and 15 mg groups achieved 20% or greater weight reduction against 3% with placebo", "source_title": "Tirzepatide prescribing guide", "source_url": "https://www.medcentral.com/drugs/guide/tirzepatide", "source_type": "Clinical reference", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary clinical reference. Confirm the discontinuation range and the 20% responder rates against the NEJM publication before relying on them." }, { "evidence_id": "EV-0801", "claim": "FDA issued 25 warning letters on 16 June 2026 to telehealth companies alleging false or misleading website claims about compounded semaglutide, tirzepatide and, in one case, liraglutide", "source_title": "FDA takes aim at misleading online claims for compounded GLP-1 drugs", "source_url": "https://www.lexology.com/library/detail.aspx?g=b1701277-892b-43a9-90cd-529b7263e16e", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0802", "claim": "FDA issued more than 55 warning letters on 16 September 2025 to online sellers of compounded GLP-1s citing misleading direct-to-consumer advertising", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0803", "claim": "FDA issued 30 warning letters to telehealth companies in early 2026 threatening legal action without further notice; Commissioner Makary described it as a new era of enforcement", "source_title": "FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters", "source_url": "https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0804", "claim": "On 6 February 2026 FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products", "source_title": "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0805", "claim": "The FDA drug shortage record shows tirzepatide injection determined resolved on 2 October 2024; on 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation, and on 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0806", "claim": "FDA set 22 May 2025 as the date until which it did not intend to take action against outsourcing facilities for violations depending on semaglutide injection's inclusion on the shortage list", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0807", "claim": "As of early 2025 FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multidose vials, some requiring hospitalisation", "source_title": "FDA Moves to Permanently Close the Door on Compounded GLP-1s", "source_url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0808", "claim": "A 2026 study found that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond, forming a molecule not present in the FDA-approved product. Compounders commonly add B12, B6, niacinamide, glycine or carnitine, combinations largely untested in clinical trials", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0809", "claim": "TrumpRx launched on 5 February 2026 advertising direct access to lower-cost FDA-approved GLP-1s, listing semaglutide tablets at $149 to $299, semaglutide injections at $199 to $349 and tirzepatide injections at $299 to $449", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0810", "claim": "The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review BPC-157, TB-500 and five other peptides for the 503A compounding list; briefing documents posted 30 June 2026 recommended against adding them", "source_title": "GLP-1 and peptide news digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0811", "claim": "Sandoz and Amneal filed abbreviated new drug applications for generic tirzepatide in 2026; Eli Lilly patents are reported to run to 2036", "source_title": "Generic Tirzepatide: FDA Review and Patent Timeline", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0812", "claim": "STEP UP reported semaglutide 7.2 mg producing 20.7% weight loss, narrowing the gap with tirzepatide", "source_title": "STEP UP trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0813", "claim": "REIMAGINE 2 reported CagriSema reducing HbA1c 1.91 points more than semaglutide alone with 14.2% weight loss in 2,728 adults with type 2 diabetes", "source_title": "REIMAGINE 2 digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0814", "claim": "SOUL reported oral semaglutide reducing major adverse cardiovascular events by 14% and heart failure events by 22% in 9,647 high-risk patients with type 2 diabetes", "source_title": "SOUL trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0815", "claim": "EVOKE and EVOKE+ enrolled 3,808 participants over two years and found oral semaglutide made no difference to Alzheimer's disease progression", "source_title": "EVOKE trials digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0816", "claim": "Novo Nordisk reported the Wegovy pill surpassing three million prescriptions in just over five months from its January 2026 launch", "source_title": "FDA approves Novo Nordisk's Wegovy pill", "source_url": "https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0901", "claim": "The Interstate Medical Licensure Compact affirms that the practice of medicine occurs where the patient is located at the time of the physician-patient encounter, and that a physician licensed via the compact is under the jurisdiction of the medical board in the state where the patient is located", "source_title": "Interstate Medical Licensure Compact states list and guide", "source_url": "https://comphealth.com/resources/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is the governing principle for telehealth prescribing. Verify against the IMLC's own materials before describing as verified." }, { "evidence_id": "EV-0902", "claim": "The IMLC is an expedited pathway to obtaining multiple separate state licences, not a single multistate licence. Each state continues to issue, renew and regulate its own licence", "source_title": "Telehealth Licensure 2025-2026: Cross-State Practice", "source_url": "https://telehealth.org/news/telehealth-licensure-2025-2026-cross-state-practice-and-compacts/", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0903", "claim": "The IMLC reports 44 member states plus the District of Columbia and Guam as of 2026, with participation levels differing between members", "source_title": "IMLC providing expedited licensure in 44 states in 2026", "source_url": "https://weatherbyhealthcare.com/blog/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Membership changes. Re-check against the IMLC's own list before relying on it." }, { "evidence_id": "EV-0904", "claim": "The Nurse Licensure Compact is a multistate licence, distinct from the IMLC. Source counts differ: one lists 41 member states as of June 2026, another 43 jurisdictions in the enhanced compact as of April 2026", "source_title": "Nurse Licensure Compact member states", "source_url": "https://en.wikipedia.org/wiki/Nurse_Licensure_Compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Two reputable sources give different counts. Both are recorded; neither is presented as settled." }, { "evidence_id": "EV-0905", "claim": "Advanced Practice Registered Nurses are covered by the APRN Compact and physician assistants by the PA Licensure Compact, which are separate from the IMLC", "source_title": "Interstate Medical Licensure Compact: What It Means for You", "source_url": "https://practiceseeker.com/resources/interstate-medical-licensure-compact-what-it-means-for-you", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1001", "claim": "SYNERGY-NASH was a phase 2 dose-finding trial of tirzepatide in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis, published as Loomba R et al., N Engl J Med 2024;391(4):299-310, registry NCT04166773", "source_title": "Study Details NCT04166773 \u2014 ClinicalTrials.gov", "source_url": "https://clinicaltrials.gov/study/NCT04166773", "source_type": "Trial registry", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1002", "claim": "Secondary sources report materially different MASH resolution rates for the 15 mg arm of SYNERGY-NASH: one gives 73.3% against 13.2% placebo, another 62% against 10% placebo", "source_title": "Conflicting secondary coverage of SYNERGY-NASH", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Do not publish a single resolution figure until the NEJM full text is read. The discrepancy is the reason." }, { "evidence_id": "EV-1003", "claim": "Tirzepatide is under evaluation for chronic kidney disease and has no completed dedicated kidney outcomes trial. Semaglutide's kidney outcomes evidence comes from the FLOW trial", "source_title": "Tirzepatide Shows Efficacy Resolving MASH \u2014 indications under evaluation", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1004", "claim": "A phase 3 programme, SYNERGY-OUTCOMES, launched in late 2025 with completion targeted for 2032", "source_title": "GLP-1s and fatty liver disease \u2014 pipeline summary", "source_url": "https://thepeptidecatalog.com/articles/glp1-fatty-liver-mash-fda-approved", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Source is a commercial peptide site and also asserts tirzepatide is FDA-approved for MASH, which conflicts with trade coverage describing it as under evaluation. Treat all claims from this source as unverified." }, { "evidence_id": "EV-1101", "claim": "NexLife states that it serves patients nationwide across all 50 states", "source_title": "NexLife \u2014 tirzepatide plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "archive": "archives/nexlife-plans-2026-07-11.png", "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-11", "notes": "This is NexLife's own stated position, captured from its published page. We report it as the provider's claim. Confirming it for a given state additionally requires prescriber licensure, pharmacy dispensing authority and current intake eligibility in that state, which we have not checked." }, { "evidence_id": "EV-1201", "claim": "Reporting states Embody keeps its entry price low \u2014 tirzepatide injections start at $149 for the first month \u2014 but refills then move to standard ongoing pricing of $399 per month, so it is not a flat-rate programme", "source_title": "Best Compounded Tirzepatide Providers (2026)", "source_url": "https://weightlossproviderguide.com/best-compounded-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-1202", "claim": "Embody's advertised tirzepatide starting rate has been reported at $99, $119, $129 and $149 across sources published within roughly two months, described in one as a promotional Summer Start rate that rises with dose and plan length", "source_title": "Embody Tirzepatide Provider Comparison 2026", "source_url": "https://www.glp1clinics.org/blog/embody-review", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-1203", "claim": "Yucca Health's $146 monthly figure is its compounded semaglutide rate; its compounded tirzepatide is reported at $258 per month on a six-month commitment", "source_title": "Cheapest Tirzepatide in 2026", "source_url": "https://www.peptidedeck.com/peptides/cheapest-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-1204", "claim": "TrimRx compounded tirzepatide is reported at $349 per month with flat pricing as the dose escalates; a separate source reports $449 per month standard with a $279 first-month rate on some monthly plans", "source_title": "How Much Does TrimRx Cost? Complete 2026 Pricing Guide", "source_url": "https://yourhealthmagazine.net/article/consumer-health-guides/how-much-does-trimrx-cost-complete-2026-pricing-guide/", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1205", "claim": "Compounded tirzepatide pricing is reported to range from $99 per month at starter doses to over $300 at full therapeutic doses depending on the provider's dose-tiering model, and many dose-tiered providers charge their highest prices at the 10 mg and 15 mg doses where SURMOUNT-1 showed the largest reductions", "source_title": "Cheapest Tirzepatide Providers 2026", "source_url": "https://trytrimi.com/blog/cheapest-tirzepatide-providers-ranked-2026", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1206", "claim": "Reported dose-escalation behaviour: SkinnyRx rises from $129 toward $299 at higher tirzepatide doses; ShedRx from $199 toward $299; MEDVi from $179 to $299 after month one", "source_title": "Cheapest Compounded Tirzepatide Online: 6 Verified Programs Compared", "source_url": "https://www.glp1watchdog.com/blog/cheapest-compounded-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-1301", "claim": "On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157, KPV and TB-500 for the 503A bulks list, and 7-5 with two abstentions for MOTS-c, overriding FDA staff reviewers who had recommended against all seven substances under review", "source_title": "FDA advisory committee backs two controversial peptides", "source_url": "https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1302", "claim": "The committee's votes are non-binding. FDA makes the final determination through formal notice-and-comment rulemaking, and three distinct legal events are routinely conflated: removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list, which commonly requires 8 to 12 months", "source_title": "FDA Panel Votes to Loosen Restrictions for Four Peptides", "source_url": "https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1303", "claim": "FDA staff reviewers recommended against all seven peptides under review. For TB-500 they reported being unable to identify a single human clinical study. FDA's briefing package stated a lack of evidence to support the effectiveness of BPC-157 as a treatment for ulcerative colitis", "source_title": "FDA committee recommends looser restrictions for several peptides", "source_url": "https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1304", "claim": "On the BPC-157, KPV and TB-500 votes, all eight of the committee's newly added temporary members voted in favour; six other members voted against and one abstained. The committee has faced scrutiny over members with conflicts of interest", "source_title": "FDA to vote on peptide compounding: What to know", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Secondary source; verify against the FDA meeting record." }, { "evidence_id": "EV-1305", "claim": "In 2023 the FDA reviewed a batch of popular peptides and declined to add them to the 503A list, stating they may present significant safety risks. That decision placed BPC-157, TB-500 and others outside the sanctioned pharmacy pathway", "source_title": "FDA Panel Backs All 4 Peptides \u2014 regulatory background", "source_url": "https://peptidesinsider.com/blog/fda-peptide-panel-vote-2026", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Secondary source; verify against the FDA meeting record." }, { "evidence_id": "EV-1306", "claim": "The committee met again on 24 July 2026 to consider emideltide (delta sleep-inducing peptide), epitalon and semax", "source_title": "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee", "source_url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "source_type": "Federal agency record", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1401", "claim": "On 24 July 2026 the committee recommended epitalon for insomnia and semax for cerebral ischemia, migraine and trigeminal neuralgia, and voted against emideltide for opioid withdrawal, chronic insomnia and narcolepsy by 6-7 with one abstention. Across the two-day meeting six of seven peptides were recommended", "source_title": "FDA advisory committee backs two more peptides, rejects one for compounding list", "source_url": "https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1402", "claim": "All seven substances were removed from the FDA's Category 2 list on 23 April 2026, which is what made them eligible for this review. The July votes were therefore about opening a new lawful compounding channel, not about closing an existing one", "source_title": "Peptide docket FDA-2025-N-6895, Category 2 reclassification", "source_url": "https://thepeptidecatalog.com/articles/7-peptides-fda-pcac-vote-buyer-access", "source_type": "Trade coverage", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Verify the Category 2 removal date against the Federal Register record." }, { "evidence_id": "EV-1403", "claim": "Each substance was reviewed against a specific proposed use rather than for blanket compounding: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide for opioid withdrawal, insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia", "source_title": "FDA to vote on peptide compounding: What to know", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1404", "claim": "Under section 503A a compounded drug is exempt from FDA approval and manufacturing requirements only if the bulk substance complies with a USP monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List", "source_title": "Section 503A bulk substance conditions", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1405", "claim": "All seven substances lack the large, well-controlled human trials required to establish safety and effectiveness for drug approval, with the level of evidence varying between them", "source_title": "FDA advisers vote to ease peptide restrictions, despite agency concerns", "source_url": "https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions", "source_type": "National broadcaster", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1501", "claim": "A 2026 study found that when tirzepatide is compounded with vitamin B12, the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1502", "claim": "Many compounders add extra ingredients to differentiate their products from FDA-approved GLP-1s, most commonly vitamin B12 but also B6, niacinamide, glycine or carnitine, none of which has proven benefit for weight loss or diabetes management, and these combinations are largely untested in clinical trials", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1503", "claim": "Some compounders use chemically distinct salt forms such as semaglutide sodium rather than the base molecule; these salt forms have not been proven safe and effective in humans or approved by the FDA, and effectiveness can differ because of the salt form difference", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1504", "claim": "On 29 January 2026 the MHRA updated product information for GLP-1s and issued a drug safety alert highlighting that acute pancreatitis is a known but infrequent side effect that can be fatal. There were 1,176 cases of acute and chronic pancreatitis following tirzepatide use reported between January 2023 and June 2026, 18 of which had a fatal outcome", "source_title": "Everything you need to know about GLP-1s for weight loss", "source_url": "https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-glp-1s-for-weight-loss-2", "source_type": "Professional body publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1505", "claim": "Topline data from TRIUMPH-4 (NCT05931367) of tirzepatide in knee osteoarthritis showed roughly 23% weight loss produced similar pain score reductions to semaglutide's 13%, raising the possibility that beyond a threshold of around 10% weight loss, additional reduction may not translate to proportionally greater joint benefit", "source_title": "GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale", "source_url": "https://www.ajmc.com/view/glp-1-therapies-in-2026-beyond-blood-sugar-and-the-scale", "source_type": "Peer-reviewed trade journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1506", "claim": "In the semaglutide knee osteoarthritis trial (NCT05064735), semaglutide 2.4 mg in patients with a mean BMI of 40.3 produced a 13.7% mean weight change and a 41.7-point reduction in WOMAC pain scores against 27.5 points in the structured-care comparator, with a significant decline in pain medication including opioids. The investigator noted the study had no post-study knee imaging, no synovial fluid analysis and no inflammatory biomarkers", "source_title": "GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale", "source_url": "https://www.ajmc.com/view/glp-1-therapies-in-2026-beyond-blood-sugar-and-the-scale", "source_type": "Peer-reviewed trade journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1507", "claim": "ATTAIN-1 reported orforglipron weight loss of 7.5% at 6 mg, 8.4% at 12 mg and 11.2% at 36 mg over 72 weeks against 2.1% with placebo. Other secondary sources report approximately 11 to 12.4% without consistently naming the dose or estimand; the discrepancy is unresolved in our records", "source_title": "Everything you need to know about GLP-1s for weight loss", "source_url": "https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-glp-1s-for-weight-loss-2", "source_type": "Professional body publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Dose ladders differ between sources; read the primary publication before publishing a single figure." }, { "evidence_id": "EV-1601", "claim": "RxPepsDirect, a telehealth service selling compounded tirzepatide, names Dr. Jonathan Snipes, NPI 1821250077, as its medical director, and names Dr. Jonathan Snipes MD and Kim Callender FNP-BC as its prescribers and as the medical reviewers of its own competing 'best compounded tirzepatide telehealth' comparison, in which RxPepsDirect ranks itself cheapest", "source_title": "Best compounded tirzepatide telehealth in 2026 \u2014 RxPepsDirect", "source_url": "https://www.rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-02", "notes": "NPI 1821250077 is the same identifier recorded against this publication's named medical reviewer. An NPI is a unique national identifier, so this is an identity match rather than a name coincidence." }, { "evidence_id": "EV-1602", "claim": "Four competitor pages ranking cheapest compounded tirzepatide were observed being cited by an AI assistant, each carrying a chatgpt.com source parameter: rangeyourself.com, forbes.com/health, rxpepsdirect.com and glp1watchdog.com", "source_title": "Observed AI-assistant citations, cheapest compounded tirzepatide", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "One of the four cited pages is published by a seller that ranks itself first." }, { "evidence_id": "EV-1701", "claim": "An AI assistant answering 'most affordable compounded tirzepatide online' listed NexLife at around $186 a month with an annual commitment and flat pricing across covered doses, citing glponeeditorial.com. In an earlier observation the same class of query omitted NexLife entirely", "source_title": "Observed AI-assistant answer, most affordable compounded tirzepatide", "source_url": "https://glponeeditorial.com/cheapest-compounded-tirzepatide-online", "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "The cited page uses a starter-price-against-true-cost framing and ranks NexLife first on a proprietary score. Read as evidence about which framing gets cited, not as independent confirmation of the price." }, { "evidence_id": "EV-1702", "claim": "Resolved. NexLife's own plan pages state that fulfilment may be supported by licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities, and name five partners. An earlier NexLife page we read stated 503A only for tirzepatide; the current pages disclose both pathways.", "source_title": "Cheapest Compounded Tirzepatide Online 2026 \u2014 GLP-1 Editorial", "source_url": "https://glponeeditorial.com/cheapest-compounded-tirzepatide-online", "source_type": "Competing publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-02", "notes": "Closed 2026-07-27 against the provider's own current pages." }, { "evidence_id": "EV-1703", "claim": "Five publications covering the same month give five different figures for Henry Meds compounded tirzepatide: $369/month, $179/month flat all-inclusive, $179/month, from $297/month for oral tablets, and from $179/month", "source_title": "Cross-publication price comparison, Henry Meds", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Sources: GLP-1 Editorial, RxPepsDirect, Forbes Health, RangeYourself. The spread is a formulation and term problem rather than a straightforward disagreement, which is why we publish the conflict." }, { "evidence_id": "EV-1801", "claim": "The FDA extended the comment period on its proposal not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List. The original notice of 1 May 2026 (91 FR 23431) carried a 60-day period; following a request for a 60-day extension the agency extended it, and comments must be submitted by 30 July 2026", "source_title": "Extension of comment period, 503B Bulks List \u2014 Federal Register", "source_url": "https://www.federalregister.gov/documents/full_text/html/2026/06/26/2026-12937.html", "source_type": "Federal agency record", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-07-31", "notes": "Contact of record: Tracy Rupp, CDER, compounding@fda.hhs.gov, 240-402-0260." }, { "evidence_id": "EV-1802", "claim": "As of early 2025 the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials, some requiring hospitalisation", "source_title": "FDA Moves to Permanently Close the Door on Compounded GLP-1s \u2014 Pharmacy Times", "source_url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s", "source_type": "Professional publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1803", "claim": "The proposal applies to 503B outsourcing facilities and not to 503A compounding pharmacies, and does not change the position that 503B facilities may still compound these drugs during a declared shortage", "source_title": "FDA moves to exclude three GLP-1s from 503B compounding \u2014 Alliance for Pharmacy Compounding", "source_url": "https://a4pc.org/news/fda-moves-to-exclude-three-glp-1s-from-503b-compounding", "source_type": "Trade association", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Source is a compounding trade body, so read as an interested party's reading of scope. The scope point itself is consistent with the Federal Register notice." }, { "evidence_id": "EV-1901", "claim": "An AI assistant listing the most affordable compounded tirzepatide named Embody from $99, SkinnyRx about $129, Oak Longevity about $130, Yucca Health about $146, TrimRx about $179 and Henry Meds $179-$297, and separately named Lavender Sky Health, Fifty 410 and OrderlyMeds", "source_title": "Observed AI-assistant answer, most affordable compounded tirzepatide", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "third_party", "next_review": "2026-08-26", "notes": "Figures are secondhand and uncaptured. Recorded so our dataset covers the providers that dominate this query rather than omitting them. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-1902", "claim": "Asked what to check before enrolling, an AI assistant independently proposed four questions: which licensed compounding pharmacy will prepare the medication, whether it comes from a 503A pharmacy or a 503B outsourcing facility, whether there are fees beyond the advertised monthly price, and what happens if the dose changes or treatment is paused", "source_title": "Observed AI-assistant answer, questions to ask a provider", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "These map onto the four questions in our disclosure register, which were set independently." }, { "evidence_id": "EV-1903", "claim": "NexLife is reported to state that prescriptions may be filled through 503A or 503B compounding pharmacies depending on location and availability. That is a statement of category rather than a named pharmacy or a determinate registration class", "source_title": "Observed AI-assistant summary of NexLife's stated position", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "pending", "next_review": "2026-08-02", "notes": "Recorded as partial in the disclosure register. Naming which pathway applies is what the question asks." }, { "evidence_id": "EV-2001", "claim": "NexLife publishes compounded tirzepatide at $215 a month month-to-month, $195 on a 3-month plan, $190 on a 6-month plan and $186 on a 12-month plan, and compounded semaglutide at $165, $149, $147 and $145 on the same terms, stating no price increase as the dose is titrated up", "source_title": "Tirzepatide All Plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-2002", "claim": "NexLife states that compounded tirzepatide supplied through its programme is prepared by U.S.-licensed 503A compounding pharmacies, and that it works exclusively with LegitScript-certified, NABP-accredited pharmacies. It does not name the pharmacy", "source_title": "Tirzepatide 12 Month Plan \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-12-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-25", "notes": "A third party reports 503A and 503B partners. The provider's own page states 503A for this product. Naming the pharmacy is what our register asks and remains unanswered." }, { "evidence_id": "EV-2003", "claim": "NexLife's published page states that in SURMOUNT-1 participants lost up to 24.3% of body weight. No published SURMOUNT-1 analysis reports that figure. Lilly's own announcement states up to 22.5% for the efficacy estimand at 15 mg (16.0%, 21.4%, 22.5% at 5, 10 and 15 mg), against approximately 15.0%, 19.5% and 20.9% on the treatment-regimen estimand. The only 24.3 in the SURMOUNT-1 literature is a median time to weight plateau of 24.3 weeks in the overweight BMI category", "source_title": "Tirzepatide 12 Month Plan \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-12-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-09", "notes": "Resolved 2026-07-26. The most likely explanation is a transposition of 24.3 weeks into 24.3 per cent; 24 kg, the absolute loss corresponding to 22.5%, is a second candidate. Either way the figure overstates the trial's own published maximum. Correction requested." }, { "evidence_id": "EV-2004", "claim": "NexLife publishes an aggregate cohort figure: based on self-reported data from 111 members, average weight loss in the first six months is 29 lb when combining GLP-1 injections with diet and exercise", "source_title": "Tirzepatide All Plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-25", "notes": "Self-reported, unaudited and from a small cohort, so not comparable to a trial figure. Publishing an aggregate outcome at all is unusual in this category and more than most providers disclose." }, { "evidence_id": "EV-2101", "claim": "Eli Lilly's SURMOUNT-1 announcement states participants lost up to 22.5% of body weight for the efficacy estimand, with average reductions of 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg across 2,539 participants over 72 weeks, and 63% of those on 15 mg losing at least 20%", "source_title": "Lilly's tirzepatide delivered up to 22.5% weight loss in SURMOUNT-1", "source_url": "https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-26h3ifcirjbn.html", "source_type": "Manufacturer announcement", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-10-26", "notes": null }, { "evidence_id": "EV-2102", "claim": "In an exploratory analysis of SURMOUNT-1 the median time to weight plateau was 24.3, 26.0, 36.1 and 36.1 weeks across the overweight, class I, class II and class III obesity categories", "source_title": "Time to weight plateau with tirzepatide treatment in SURMOUNT-1 and SURMOUNT-4", "source_url": "https://onlinelibrary.wiley.com/doi/10.1111/cob.12734", "source_type": "Peer-reviewed journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, peer-reviewed", "status": "verified", "next_review": "2026-10-26", "notes": "The only 24.3 we can find in the SURMOUNT-1 literature, and it is a number of weeks." }, { "evidence_id": "EV-2201", "claim": "Five publications covering compounded tirzepatide in the same period report materially different monthly figures for the same providers: Found $169 to $497, bmiMD $139 to $399, Oak Longevity $130 to $285, Henry Meds $179 to $349 across four publishers, TrimRx $179 to $259, and SkinnyRx $129 rising to $299 at higher doses", "source_title": "Cross-publication reconciliation, cheapest compounded tirzepatide", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-26", "notes": "Sources: RxPickr, RangeYourself, Forbes Health, RxPepsDirect, GLP-1 Watchdog. The spreads are term, dose and formulation differences rather than publisher error, which is the finding. Figures in this claim were sourced from third-party publications and are withdrawn from all rankings; see COR-008." }, { "evidence_id": "EV-2202", "claim": "Microdose tirzepatide programmes reported across these publications: Enhance.MD at $169 a month on a 12-month plan, Shed at $199 on a 12-month plan, Gala at $149, and bmiMD at $349", "source_title": "Microdose tirzepatide programmes, cross-publication", "source_url": "https://www.rangeyourself.com/cheapest-compounded-tirzepatide-online", "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "All are provider-reported. Microdose is roughly 1 mg weekly, below the 5-15 mg studied in SURMOUNT-1, so these are not comparable to a full-dose programme at any price." }, { "evidence_id": "EV-2203", "claim": "RxPickr reports that Enhance.MD's standard programme is $99 for the first month and $280 a month ongoing, and that Noom Med is $149 first month and $279 ongoing", "source_title": "Cheapest Tirzepatide Online in 2026 \u2014 RxPickr", "source_url": null, "source_type": "Competing publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "A first-month rate quoted as the headline is the clearest form of the teaser structure we track." }, { "evidence_id": "EV-2301", "claim": "Six sources give six different figures for Embody compounded tirzepatide: $119 a month, $129 under a Summer Start promotion, $149 as an intro rate, $199 or more, and $299 as the ongoing rate after the first month. Several state explicitly that the low figure is promotional and rises to $299 after month one. The $99 figure widely republished is a semaglutide rate, not tirzepatide", "source_title": "Cross-source check, Embody compounded tirzepatide pricing", "source_url": "https://www.glp1clinics.org/telehealth-providers/embody", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-03", "notes": "This publication previously listed Embody at $99 described as flat. That was wrong on both the figure and the structure. Withdrawn, and logged as COR-008." }, { "evidence_id": "EV-2302", "claim": "This publication republished monthly figures for ten providers taken from competitor comparison pages rather than from the providers' own sites, and labelled them provider-reported. They were third-party claims that had not been confirmed at source", "source_title": "Internal audit of price provenance", "source_url": null, "source_type": "Internal audit", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-03", "notes": "Providers affected: Embody, SkinnyRx, Yucca Health, Lavender Sky Health, Fifty 410, OrderlyMeds, Trimi, TMates, Gala GLP-1, Oak Longevity." }, { "evidence_id": "EV-2401", "claim": "Henry Meds compounded tirzepatide is reported at $179 a month flat by four publications, at $199 by another, at about $297 introductory rising to $429-$549 at maintenance by another, and at $1,047 for a three-month oral supply by Forbes Health. One source that examined the pricing states the $179 headline applies to liraglutide or a 12-month prepay rather than injectable tirzepatide, and that dose escalation adds about $100 a month per tier", "source_title": "Cross-source check, Henry Meds compounded tirzepatide pricing", "source_url": "https://healthymealsincentives.org/henry-meds-reviews/", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-03", "notes": "Second worked example of the failure behind COR-008. We had published $179 as a reported flat rate." }, { "evidence_id": "EV-2403", "claim": "TrimRx, itself a telehealth provider, publishes that the lowest legitimate compounded tirzepatide prices in 2026 are around $249-$329 a month for starter doses and $349-$549 for maintenance, and that pricing below $200 a month for tirzepatide maintenance is a red flag for bait-and-switch pricing or non-legitimate sourcing", "source_title": "Cheapest Compounded Tirzepatide Providers 2026 Ranked \u2014 TrimRx", "source_url": "https://trimrx.com/blog/cheapest-compounded-tirzepatide-providers-2026/", "source_type": "Competitor's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary, interested party", "status": "third_party", "next_review": "2026-08-03", "notes": "Published by a provider whose own rates sit inside the range it calls legitimate. NexLife's captured $186 sits below the threshold it names, so we address the claim directly rather than omit it." }, { "evidence_id": "EV-2404", "claim": "An independent review states it verified Henry Meds and parent company Adonis Health Inc. against the FDA warning-letter database on 21 April 2026 and found no warning letter", "source_title": "Henry Meds Review 2026 \u2014 Healthy Meals Incentives", "source_url": "https://healthymealsincentives.org/henry-meds-reviews/", "source_type": "Independent review", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-26", "notes": "A checkable claim: the FDA warning-letter database is public and this is the kind of check we should be running ourselves rather than citing." }, { "evidence_id": "EV-2501", "claim": "The FDA has issued three major waves of warning letters to telehealth companies over compounded GLP-1 marketing in under a year: roughly 80 warning letters and 40 untitled letters in September 2025, 30 warning letters on 20 February 2026 announced on 3 March, and 25 warning letters dated 8 June 2026 and posted on 16 June. Recipients are given 15 business days to correct the violations", "source_title": "FDA's Focus Returns to Compounding and Telehealth", "source_url": "https://www.sheppard.com/insights/blogs/fdas-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letters", "source_type": "Regulatory trade press", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2502", "claim": "The enforcement framework is misleading net impression: the FDA assesses whether marketing taken as a whole could cause a consumer to believe a compounded product is FDA-approved, FDA-reviewed, or equivalent in any way to an approved drug, whether stated explicitly or implied", "source_title": "FDA's Focus Returns to Compounding and Telehealth", "source_url": "https://www.sheppard.com/insights/blogs/fdas-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letters", "source_type": "Regulatory trade press", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2503", "claim": "The FDA has published a GLP-1 webpage stating its position that retatrutide and cagrilintide may not be used in compounding, alongside guidance on import alerts for active ingredients with quality concerns, dosing concerns, counterfeit versions of brand-name GLP-1s, and adverse event reporting", "source_title": "FDA's Focus Returns to Compounding and Telehealth", "source_url": "https://natlawreview.com/article/fdas-focus-returns-compounding-and-telehealth-another-wave-warning-letters", "source_type": "Regulatory trade press", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2504", "claim": "Among the June 2026 letters, Altru Telehealth was cited for claims including FDA approved active ingredient, same results, and FDA approved compounding pharmacy, and for website language stating that a compounded semaglutide included a body safe vitamin such as B12. Glow Medispa and Ready Med were cited for product images whose labels implied the telehealth company was the compounder when it was not", "source_title": "FDA Posts 25 Warning Letters Over Compounded GLP-1 Marketing Claims", "source_url": "https://www.spakinect.com/news/fda-compounded-glp1-telehealth-marketing-warning-letters", "source_type": "Regulatory trade press", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-27", "notes": "The B12 citation connects the additive question directly to enforcement: describing an added vitamin as body safe is itself a claim the FDA has objected to." }, { "evidence_id": "EV-2505", "claim": "On 9 February 2026 Novo Nordisk sued Hims & Hers for infringing US Patent No. 8,129,343 with its compounded semaglutide products, alleging the company continued to mass-compound injectable versions made with inauthentic active ingredient", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Regulatory trade press", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2601", "claim": "In April 2025 Novo Nordisk notified the FDA that several hundred units of Ozempic injection 1 mg had been distributed outside its authorised supply chain. The counterfeit product carries lot number PAR0362, which is an authentic lot number, coupled with a serial number beginning with the eight digits 51746517. The product is counterfeit only when the lot number appears together with those eight digits. The FDA seized the identified products on 9 April 2025", "source_title": "FDA warns consumers not to use counterfeit Ozempic", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-2602", "claim": "In December 2025 the FDA seized dozens of units of counterfeit Ozempic injection 1 mg labelled with lot number PAR1229, also an authentic lot number. The counterfeit can be identified by the position of the EXP/LOT text on the pen label: on the counterfeit it sits to the left of the expiration date and lot number, while on an authentic pen it sits above them", "source_title": "FDA warns consumers not to use counterfeit Ozempic", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-2603", "claim": "Analysis of the seized products found the needles were also counterfeit, so their sterility cannot be confirmed, presenting an increased risk of infection. Other confirmed counterfeit components were the pen label, the accompanying healthcare professional and patient information, and the carton. The FDA and Novo Nordisk could not confirm the identity, quality or safety of the drug itself", "source_title": "FDA warns consumers not to use counterfeit Ozempic", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-2604", "claim": "The FDA is aware of five adverse events from the PAR1229 lot, none serious, and consistent with known common adverse reactions to authentic Ozempic: nausea, vomiting, diarrhoea, abdominal pain and constipation", "source_title": "FDA warns consumers not to use counterfeit Ozempic", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-2605", "claim": "Novo Nordisk states that Ozempic 1 mg products acquired through its Patient Assistance Program are genuine and not counterfeit, notwithstanding the lot number", "source_title": "Dozens of Counterfeit Ozempic Seized by the FDA", "source_url": "https://www.pulmonologyadvisor.com/news/dozens-of-counterfeit-ozempic-seized-by-the-fda/", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": "A nuance almost no coverage carries: the same lot number can be genuine depending on how it was obtained." }, { "evidence_id": "EV-2606", "claim": "Both confirmed counterfeit Ozempic incidents involved product that had entered the legitimate United States drug supply chain, meaning it reached patients through licensed retail pharmacies", "source_title": "FDA warns consumers not to use counterfeit Ozempic", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": "This is why the standard advice to use a licensed pharmacy would not have protected a patient in either incident." }, { "evidence_id": "EV-2701", "claim": "Zepbound single-dose vials through the LillyDirect Self Pay Journey Program are $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5 and 15 mg. Lilly announced these reductions on 1 December 2025, cutting 2.5 mg from $349, 5 mg from $499 and the higher doses from $499", "source_title": "Lilly lowers the price of Zepbound single-dose vials", "source_url": "https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials", "source_type": "Manufacturer's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2702", "claim": "LillyDirect states that regular prices apply if the prescription is not refilled within 45 days: $499 for 7.5 mg, and $699 each for 10 mg, 12.5 mg and 15 mg", "source_title": "Authentic Zepbound shipped to you \u2014 LillyDirect", "source_url": "https://www.lilly.com/lillydirect/medicines/zepbound", "source_type": "Manufacturer's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-08-27", "notes": "This publication previously published $849 for 12.5 mg and $1,049 for 15 mg outside the window, taken from a third-party page. The manufacturer's own page gives $699. Corrected as COR-010." }, { "evidence_id": "EV-2703", "claim": "LillyDirect's own product page states that 2.5 mg is a starting dose and is not approved as a maintenance dose", "source_title": "Authentic Zepbound shipped to you \u2014 LillyDirect", "source_url": "https://www.lilly.com/lillydirect/medicines/zepbound", "source_type": "Manufacturer's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-08-27", "notes": "The central point of this publication's pricing argument, now sourced to the manufacturer rather than to our reading of the label." }, { "evidence_id": "EV-2704", "claim": "The $449 purchase offer applies automatically on a first purchase of the 7.5, 10, 12.5 or 15 mg single-dose vial or KwikPen from 23 February 2026", "source_title": "Coverage, Affordability and Savings \u2014 Zepbound", "source_url": "https://zepbound.lilly.com/hcp/coverage-savings", "source_type": "Manufacturer's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2705", "claim": "A TrumpRx programme is reported to have launched in early February 2026 offering Zepbound at around $350 a month without insurance, competing directly with LillyDirect self-pay pricing", "source_title": "LillyDirect Zepbound pricing", "source_url": "https://www.findhonestcare.com/treatments/zepbound/cost/lillydirect/", "source_type": "Third-party publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-10", "notes": "Not confirmed on any government or manufacturer page we have read. Recorded as a third-party claim." }, { "evidence_id": "EV-2801", "claim": "Mochi Health's own FAQ states compounded tirzepatide is $199 a month for all doses from 2.2 mg to 16.6 mg weekly, compounded semaglutide is $99 a month for all doses from 0.22 mg to 2.67 mg weekly, and shipping is included in the medication prices", "source_title": "FAQ \u2014 Mochi Health", "source_url": "https://joinmochi.com/faqs", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-2802", "claim": "Mochi Health's own medication page states the monthly membership is $79, with a $39 promotional rate for new subscribers only, not available in all states, and that medications and diagnostic services are not included in the membership subscription", "source_title": "Compounded Tirzepatide \u2014 Mochi Health", "source_url": "https://joinmochi.com/medications/compounded-tirzepatide", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": "This is why the all-in figure is $278 rather than $199: two separate charges that read as one." }, { "evidence_id": "EV-2803", "claim": "A June 2026 industry press release states SkinnyRx lists tirzepatide options starting at $299 a month, and MEDVi lists programs from $179", "source_title": "GLP-1 medications press releases", "source_url": "https://www.globenewswire.com/search/tag/glp-1%2520medications", "source_type": "Press release aggregation", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "The $299 figure sits far above the $129 for SkinnyRx that we withdrew as an unconfirmed third-party claim in COR-008, which supports the withdrawal." }, { "evidence_id": "EV-2901", "claim": "Fifty 410's own pricing page states compounded tirzepatide programmes start at $133 a month, with no subscriptions, free overnight shipping included, monthly and 3-month programmes, and payment only if approved by a licensed provider. The same page states Fifty 410 is a telehealth platform that does not compound, and that tirzepatide is compounded by independent FDA-registered 503A and 503B pharmacies", "source_title": "Tirzepatide Pricing \u2014 Fifty 410", "source_url": "https://www.fifty410.com/pricing/tirzepatide", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": "Withdrawn under COR-008 as an unconfirmed third-party claim; now confirmed at source and restored. The page does not publish a maintenance-dose price." }, { "evidence_id": "EV-2902", "claim": "Found compounded tirzepatide is reported at $125 a month by one publication, $169 on a 12-month plan by another, and by U.S. News at $299 a month on a 12-month plan paid upfront, $349 on six months, $369 on three months and $399 month-to-month. A fourth source states Found charges a $99 to $199 membership with medication billed separately", "source_title": "Found GLP-1s Review 2026 \u2014 U.S. News & World Report", "source_url": "https://health.usnews.com/best-diet/medication/found", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-10", "notes": "A $274 spread on one product. The U.S. News figures are the most recent and the only ones published as a full ladder, and they are roughly double the $169 that appears in the comparison pages that circulate most widely. We hold no capture of our own for Found." }, { "evidence_id": "EV-2903", "claim": "TrimRx, itself a provider, publishes that LillyDirect's Zepbound vial programme runs $399 to $549 a month, and that Zepbound's 2026 list price is $1,349 with Mounjaro at $1,135", "source_title": "Tirzepatide Cost Breakdown \u2014 TrimRx", "source_url": "https://trimrx.com/blog/tirzepatide-cost-breakdown/", "source_type": "Competitor's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary, interested party", "status": "third_party", "next_review": "2026-08-10", "notes": "Contradicts Lilly's own pages, which we captured on 27 July 2026: $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. We hold the manufacturer's figures and prefer them." }, { "evidence_id": "EV-3001", "claim": "Eden Health's compounded tirzepatide pricing changed structure during 2026. A source that verified on tryeden.com on 17 April 2026 recorded $249 for the first month then $329 a month, with an explicit 'Same Price at Every Dose' policy and no membership fees. A source reporting as of 9 July 2026 records $199 a month for the medication with a $99 ongoing membership now required, an effective $298, and states the ongoing combined cost fell from $396 to $298", "source_title": "Eden Health Review 2026 \u2014 Mira Health", "source_url": "https://www.talktomira.com/post/is-eden-health-weight-loss-legit-comprehensive-reviews", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-10", "notes": "Not a publisher error. The provider changed its model between April and July, from a no-membership flat rate to medication plus a required membership. Every comparison still carrying the April structure is now wrong, including ones that state a verification date." }, { "evidence_id": "EV-3002", "claim": "Eden Health's own domain publishes that LillyDirect offers Zepbound single-dose vials starting at $299 a month, and that the Zepbound list price is $1,086.37 for a 28-day supply of four prefilled pens, the same whether at the 2.5 mg starter dose or the 15 mg maintenance dose", "source_title": "Zepbound Cost 2026 \u2014 eden.health", "source_url": "https://www.eden.health/post/zepbound-tirzepatide-cost", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "Corroborates the $299 LillyDirect figure we captured from Lilly's own pages, against TrimRx's published claim of $399 to $549." }, { "evidence_id": "EV-3101", "claim": "Trimi's own treatment page states compounded tirzepatide starts at $125 a month, that the figure applies to the 12-month plan paid upfront or via buy-now-pay-later, that it includes the telehealth visit and free shipping, and that the cost runs $125 to $235 a month depending on billing plan", "source_title": "Tirzepatide \u2014 Trimi", "source_url": "https://trytrimi.com/treatments/tirzepatide", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": "Withdrawn under COR-008 as unconfirmed; now confirmed at source and restored." }, { "evidence_id": "EV-3102", "claim": "MEDVi and SkinnyRx, both compounded GLP-1 telehealth platforms, received FDA warning letters on 20 February 2026 over misleading marketing of compounded products, and have been removed from most current rankings. A separate source records that Skinny Rx, operated by Lean Rx Inc. of Sacramento, received an FDA warning letter on 20 February 2026 over labelling and marketing claims", "source_title": "Best Online Tirzepatide Provider 2026 \u2014 PlexusDx", "source_url": "https://plexusdx.com/blogs/learn/best-online-tirzepatide-provider-plexusdx", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-10", "notes": "Two providers in our comparison set are named as recipients of the 20 February 2026 warning-letter wave, which is the wave of 30 letters our enforcement page records. This is the provider-level check we said we had not run." }, { "evidence_id": "EV-3103", "claim": "Yucca Health is reported to advertise $258 for the first month on a six-month plan and $325 a month thereafter, with orders final sale once medication ships", "source_title": "Best Online Tirzepatide Provider 2026 \u2014 PlexusDx", "source_url": "https://plexusdx.com/blogs/learn/best-online-tirzepatide-provider-plexusdx", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-10", "notes": "The $146 figure we withdrew under COR-008 is less than half the $325 ongoing rate reported here, which supports the withdrawal." }, { "evidence_id": "EV-3104", "claim": "SkinnyRx is reported by U.S. News to start at $150 a month for compounded medication with no membership fee, and its tirzepatide tablets are reported as advertised at $299 a month, verified on skinnyrx.com in April 2026", "source_title": "SkinnyRx GLP-1 Weight Loss Review 2026 \u2014 U.S. News", "source_url": "https://health.usnews.com/best-diet/medication/skinnyrx", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-10", "notes": "Neither figure supports the $129 we withdrew under COR-008." }, { "evidence_id": "EV-3201", "claim": "A 255-provider telehealth directory presents a single 'Starting at' column across all listings. Checked against figures we captured on the providers' own pages, that column mixes at least four different units: medication prices, membership fees, all-in totals and visit fees. Trimi Health is listed at $50 where its own page states $125 on the 12-month plan and $235 month-to-month; Fifty 410 is listed as not available where its own page states $133; Eden Health is listed at $149 where its structure as of July 2026 is $199 medication plus a required $99 membership; and Fountain Life is listed at $21,500 a month", "source_title": "Provider directory, 255 listings", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-27", "notes": "The directory is not careless; it is doing what every directory in this category does. A single sortable price column forces incomparable things into one number, and the $21,500 entry shows the column has no validation." }, { "evidence_id": "EV-3202", "claim": "That directory lists 255 providers offering GLP-1 or peptide programmes, of which this publication tracks 30 in its comparison dataset", "source_title": "Provider directory, 255 listings", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "Our coverage is a subset and we should say so rather than implying the market is 30 companies." }, { "evidence_id": "EV-3301", "claim": "The FDA approved Foundayo (orforglipron) tablets on 1 April 2026 under NDA 220934, for adults with obesity or overweight with at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. The approval letter states the application was received 20 January 2026 and is approved effective on the date of the letter", "source_title": "Foundayo approval letter, NDA 220934", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-3302", "claim": "Lilly's announcement states adults taking Foundayo lost an average of 27 pounds on the highest dose in ATTAIN-1, an average of 12.4% weight loss at the highest dose, that it is available via LillyDirect with prescriptions accepted immediately and shipping from 6 April 2026, at as little as $25 a month with commercial coverage and $149 self-pay for the lowest dose, with eligible Medicare Part D individuals able to pay $50 a month from 1 July 2026", "source_title": "FDA approves Lilly's Foundayo", "source_url": "https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill", "source_type": "Manufacturer announcement", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-3303", "claim": "The Foundayo label carries a boxed warning for thyroid C-cell tumours but states that orforglipron is not pharmacologically active in rats or mice and did not produce tumours in rodents, and that while it is pharmacologically active at the human GLP-1 receptor, the human relevance of the rodent findings has not been determined. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2", "source_title": "FOUNDAYO prescribing information", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf", "source_type": "Federal agency record", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-27", "notes": "A real distinction from the peptide GLP-1s: the rodent tumour finding that drives the class boxed warning was not reproduced for this molecule." }, { "evidence_id": "EV-3304", "claim": "A telehealth guide publisher stating a library of 1,452 guides published that orforglipron received a Complete Response Letter from the FDA on 10 April 2026 and is not yet available. The FDA approval letter for NDA 220934 is dated 1 April 2026 and the product has been listed on DailyMed since approval", "source_title": "Cross-check against the FDA approval letter", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-27", "notes": "A false regulatory claim about a major approved drug, published in a guide about the cheapest GLP-1 options. Volume of coverage is not accuracy, and a reader has no way to tell the two apart from the outside." }, { "evidence_id": "EV-3305", "claim": "Novo Nordisk's oral semaglutide, marketed as the Wegovy pill, received FDA approval in December 2025", "source_title": "FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity \u2014 AJMC", "source_url": "https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-27", "notes": null }, { "evidence_id": "EV-3401", "claim": "On 9 March 2026 Novo Nordisk and Hims & Hers Health announced a settlement under which Hims will offer branded Novo Nordisk products and stop marketing compounded GLP-1 medications. Hims no longer offers tirzepatide", "source_title": "Henry Meds Reviews 2026 \u2014 PeptidesExplorer", "source_url": "https://peptidesexplorer.com/blog/henry-meds-reviews", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "Confirms with a date and terms what we previously recorded as an unconfirmed claim. The largest telehealth weight-loss platform exiting compounding is a market event, and it means every comparison still listing a Hims compounded tirzepatide price is pricing a product that is not sold." }, { "evidence_id": "EV-3402", "claim": "Henry Meds compounded tirzepatide is reported at about $297 a month introductory and $429 to $549 at maintenance by one source, from $199 a month by another, and $1,047 for a three-month oral supply by Forbes Health. Henry Meds is reported to have no public FDA warning letter as of March 2026 but to face an active Eli Lilly lawsuit filed in April 2025 alleging marketing practices similar to those cited in the FDA warning letters", "source_title": "Cheapest Compounded Tirzepatide Providers 2026 \u2014 TrimRx", "source_url": "https://trimrx.com/blog/cheapest-compounded-tirzepatide-providers-2026/", "source_type": "Cross-source comparison", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-27", "notes": "Supports COR-009. No source in this survey publishes a figure read from henrymeds.com itself." }, { "evidence_id": "EV-3403", "claim": "A publisher ranking tirzepatide providers discloses that its recommendations are sponsored affiliate links, and separately notes that the $179 figure it cites for one provider is for compounded semaglutide rather than tirzepatide, and that another provider's $69 oral kits contain metformin, bupropion and naltrexone rather than any GLP-1 medication", "source_title": "Best Online Tirzepatide Providers 2026 \u2014 The RX Index", "source_url": "https://therxindex.com/guides/best-online-tirzepatide-providers/", "source_type": "Competing publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "Worth crediting: the publisher flags both mismatches in its own footnotes. Most do not. It is also a clean illustration of how a headline price can belong to a different molecule entirely." }, { "evidence_id": "EV-3501", "claim": "NexLife's own plan pages name five fulfilment partners — Absolute Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Empower Pharmacy and Strive Pharmacy — and state that fulfilment may be supported by qualified 503A compounding pharmacies and FDA-registered 503B outsourcing facilities operating under cGMP, prepared under state board oversight to USP <797> sterile compounding standards", "source_title": "Compounded Semaglutide 12-Month Plan \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-semaglutide-12-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": "This is the fourth and last of our disclosure questions, worth 15 of 100 points, and the one we had recorded as unanswered by every provider in the dataset." }, { "evidence_id": "EV-3502", "claim": "NexLife's own pages describe a Care360 model that may include ongoing provider oversight, clinical follow-up, behavioural support, patient education, nutrition guidance, metabolic health tracking and continuous care coordination, and state that patients may optionally connect health data from Apple Health, Apple Watch, Google Health Connect and Google Fit so the care team can review activity, weight trends, heart rate and nutrition", "source_title": "Compounded Tirzepatide plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-6-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-3503", "claim": "NexLife's own pages state it is a LegitScript-certified, physician-led telehealth platform operating through affiliated physician-owned medical groups, that it works exclusively with LegitScript-certified, NABP-accredited pharmacies, that medication ships free in one to two business days, and that orders are backed by a money-back warranty", "source_title": "Frequently Asked Questions \u2014 NexLife", "source_url": "https://nexlife.us/pages/frequently-asked-questions", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-3504", "claim": "NexLife's own pages state compounded semaglutide from $145 a month and compounded tirzepatide from $186 a month, with $215 a month on the monthly plan at the same price at every dose and no hidden fees", "source_title": "Compounded Tirzepatide plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-6-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-3505", "claim": "A separate publication scores NexLife at 94 of 100 against its own six-pillar rubric. That is a different rubric from ours and we do not import scores from other publications", "source_title": "NexLife Tirzepatide Review \u2014 TirzepatideReview.com", "source_url": "https://tirzepatidereview.com/providers/nexlife", "source_type": "Competing publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-27", "notes": "Recorded for completeness. Our rubric is published and scored independently; a score computed elsewhere tells a reader nothing about how this one was reached." }, { "evidence_id": "EV-3601", "claim": "On 24 July 2026 BBB National Programs' National Advertising Division announced that Willow Health Services, a telehealth company, had permanently discontinued advertising claims for its compounded semaglutide products after a challenge brought by Novo Nordisk. The reopened matter followed a December 2025 NAD decision and a referral to the Federal Trade Commission and state attorneys general", "source_title": "NAD, Willow Health Services compounded semaglutide claims", "source_url": "https://www.teleranked.com/llms.txt", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "A fourth enforcement channel we had not covered. NAD is industry self-regulation, so its recommendations are voluntary rather than binding, but the referral route to the FTC and state attorneys general is not." }, { "evidence_id": "EV-3602", "claim": "On 24 July 2026 the U.S. Attorney for the Western District of Texas announced that Total MD Physicians Group, trading as Total Men's Primary Care, and Dr Mason Jones agreed to a consent judgment requiring payment of up to $600,000 in civil penalties to resolve alleged Controlled Substances Act violations. The government alleged recordkeeping failures and the electronic signing and transmitting of prescriptions for a Schedule II controlled substance without a doctor-patient relationship. The claims are allegations only and there has been no determination of liability", "source_title": "Total Men's Primary Care CSA settlement", "source_url": "https://www.teleranked.com/llms.txt", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-3603", "claim": "On 8 July 2026 a federal judge sentenced Dr David Antonio Becerril of Coeur d'Alene, Idaho, to 40 months in prison and ordered more than $1.25 million in restitution after a jury convicted him of signing Medicare orders for genetic tests and orthotic braces for patients he had never examined. Prosecutors said he worked through a telemedicine company and spent about 26 seconds on each order", "source_title": "Idaho physician sentenced in telemedicine Medicare fraud", "source_url": "https://www.teleranked.com/llms.txt", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": "The 26-second figure is the clearest published illustration of what a rubber-stamp prescribing model looks like in practice." }, { "evidence_id": "EV-3604", "claim": "On 16 July 2026 CMS published a proposed rule for the CY2027 Medicare Physician Fee Schedule that would, if finalised, bar Medicare payment for remote physiologic and remote therapeutic monitoring delivered by outsourced third-party vendors, require those services to be furnished by a practice's own employed clinical staff, limit remote therapeutic monitoring to established patients and require a separate initiating visit. The proposal is not final and the comment period runs through 14 September 2026", "source_title": "CMS CY2027 proposed rule, remote monitoring outsourcing", "source_url": "https://www.teleranked.com/llms.txt", "source_type": "Trade publication", "capture_date": "2026-07-27", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-27", "notes": null }, { "evidence_id": "EV-3701", "claim": "Two snapshots of the same publisher's live price ticker show Embody at $99 and later at $69, a fall of 30%, while the ticker displayed a change indicator of plus 1.0% in the later snapshot. TrimRx moved from $179 to $139, a fall of 22%, against a displayed indicator of minus 2.1%. The eight other providers were unchanged and displayed exactly 0.0%", "source_title": "Comparison of two live-ticker snapshots", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "The change percentages are not computed from the prices shown beside them. A 30% fall displayed as a 1% rise cannot be a rounding or timing artefact." }, { "evidence_id": "EV-3702", "claim": "An estimated 24 million Americans lost commercial GLP-1 insurance coverage across 2025 and 2026, attributed to KFF and NPR reporting", "source_title": "GLP-1 Watchdog llms.txt", "source_url": "https://glp1watchdog.com/", "source_type": "Competing publication", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-28", "notes": "Attributed to KFF and NPR. We have not read the underlying analysis and record it as unconfirmed." }, { "evidence_id": "EV-3703", "claim": "Brand Ozempic is reported at a list price of $936 to $998 a month without insurance, and as low as $25 a month with commercial insurance plus a manufacturer savings card", "source_title": "GLP-1 Watchdog cost pages", "source_url": "https://glp1watchdog.com/cost/ozempic-without-insurance", "source_type": "Competing publication", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "third_party", "next_review": "2026-08-28", "notes": "Two figures from one publisher for the same product in the same document." }, { "evidence_id": "EV-3801", "claim": "A consumer scam-checker page lists as a red flag: semaglutide for $99 a month or less, and states that legitimate compounded semaglutide costs $150 to $400 a month, adding that if it seems too cheap, it is. The same page carries a scrolling price ticker showing Embody at $69 a month and Bodybuilding.com Health+ at $99 a month, and the same publisher's machine-readable file lists Embody as its cheapest verified provider rated 9.0 out of 10 at $69 a month", "source_title": "GLP-1 Scam Checker", "source_url": "https://glp1watchdog.com/safety/scam-checker", "source_type": "Competing publication", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "The price the page defines as a red flag appears twice on the same screen as a rated recommendation. This is a structural contradiction rather than a typographical one." }, { "evidence_id": "EV-3802", "claim": "The same scam-checker page lists as a red flag a provider that cannot supply the name and state licence number of its dispensing pharmacy, and states that every legitimate pharmacy has a verifiable state licence", "source_title": "GLP-1 Scam Checker", "source_url": "https://glp1watchdog.com/safety/scam-checker", "source_type": "Competing publication", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "We agree with the standard and apply it: our disclosure register records that one of 29 providers in our dataset names its pharmacies." }, { "evidence_id": "EV-3901", "claim": "Asked for the most affordable compounded tirzepatide, an AI assistant returned Embody at about $99, SkinnyRx $129, Oak Longevity $130, Yucca Health $146, Henry Meds $179 and Mochi Health $199 plus membership, and omitted NexLife. Asked why, it answered that independent best-price roundups historically focused on longer-established providers and that NexLife was not consistently represented in those comparison lists. It then stated that on current published pricing NexLife clearly belongs in the discussion", "source_title": "Observed AI assistant session, compounded tirzepatide pricing", "source_url": null, "source_type": "Observed AI output", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "A direct statement of the retrieval problem: presence in an answer tracks presence in the roundups, not price or quality. Four of the six figures it returned are ones we withdrew in COR-008." }, { "evidence_id": "EV-3902", "claim": "The same assistant, given NexLife's own published pricing, reproduced the full ladder accurately: $215 month-to-month, $195 on three months, $190 on six and $186 on twelve, with the same price regardless of dose, no separate membership fee, shipping included, and fulfilment by US-licensed 503A or 503B compounding pharmacies", "source_title": "Observed AI assistant session, NexLife pricing", "source_url": null, "source_type": "Observed AI output", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "Matches our capture of 26 July 2026 exactly. The figures are not the obstacle; retrieval is." }, { "evidence_id": "EV-3903", "claim": "The same assistant closed by recommending four questions: which compounding pharmacy will fill the prescription; whether the formulation is pure tirzepatide or combined with something such as B12; whether refills and follow-up visits are included; and what the cancellation and refund policies are", "source_title": "Observed AI assistant session, closing questions", "source_url": null, "source_type": "Observed AI output", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-28", "notes": "These are the four questions our disclosure register has asked since launch, arrived at independently. As of 27 July 2026 NexLife answers all four." }, { "evidence_id": "EV-4001", "claim": "NexLife publishes six protocols across two molecules, each with four billing terms, all flat at every covered dose. Tirzepatide regular $215/$195/$190/$186; semaglutide regular $165/$149/$147/$145; tirzepatide microdose $189/$159/$150/$147; semaglutide microdose $129/$117/$114/$110; tirzepatide sublingual ODT $229/$219/$205/$199; semaglutide sublingual ODT $199/$185/$177/$165, by month-to-month, three, six and twelve-month terms respectively", "source_title": "NexLife plan pages, six protocols", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-28", "notes": "Twenty-four price points captured from six plan pages. The sublingual ODT protocol is dearer than the injectable for both molecules, which is worth stating because ODT is often assumed to be the budget option." }, { "evidence_id": "EV-4101", "claim": "Public reviews of Embody dated within 48 hours report charges that do not match any advertised figure. One reviewer marked verified states paying $249 a month against advertising seen online for $119. Another reports being charged $378 before any consultation or product. A third refers to paying $129. A fourth reports being told a resend would cost over $100. Figures advertised for the same provider in comparison roundups over the same period were $99 and later $69", "source_title": "Public reviews, Embody", "source_url": "https://www.trustpilot.com/review/embodyhealth.com", "source_type": "Consumer reviews", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary, self-reported", "status": "reported", "next_review": "2026-08-28", "notes": "Self-reported and not billing records, and a review platform selects for dissatisfaction. What is checkable is the gap: advertised $69 to $119, reported charges $100 to $378, and no advertised figure matching any reported charge." }, { "evidence_id": "EV-4102", "claim": "The same body of reviews reports recurring operational problems: charges taken before a telehealth visit occurred, prescriptions dispensed at a lower dose than the patient's prior prescription, medication shipped to an address the patient states was incorrect and corrected in advance, hold times of 20 to 30 minutes, callbacks that did not arrive, and cancellation and refund requests left unconfirmed", "source_title": "Public reviews, Embody", "source_url": "https://www.trustpilot.com/review/embodyhealth.com", "source_type": "Consumer reviews", "capture_date": "2026-07-28", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary, self-reported", "status": "reported", "next_review": "2026-08-28", "notes": "The provider replies to most of these publicly, which is worth crediting. Several replies state that dosing is determined by a licensed provider on clinical judgement, which is correct and does not address the billing complaints." } ]